Clinical predictors of response to anakinra in patients with heart failure

International Journal of Cardiology

Volumn 173, Issue 3, 2014, Pages 537-539

  Canada, Justin M ^a   Van Tassell, Benjamin W ^a   Christopher, Sanah ^a   Oddi, Claudia ^a   Abouzaki, Nayef A ^a   Gambill, Michael L ^a   Mueller, George ^a   Melchior, Ryan ^a   Shah, Keyur B ^a   Dinarello, Charles A ^b   Abbate, Antonio ^a   Arena, Ross ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Aerobic capacity; Diastole; Heart failure; Inflammation

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOCARDIOGRAPHY; DUKE ACTIVITY STATUS INDEX; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; LETTER; MALE; MIDDLE AGED; OXYGEN UPTAKE EFFICIENCY SLOPE; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE; DRUG EFFECTS; EXERCISE TEST; PATHOPHYSIOLOGY; PILOT STUDY; PREDICTIVE VALUE; PROCEDURES;

EXERCISE TEST; FEMALE; HEART FAILURE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS;

EID: 84899554230     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.03.023     Document Type: Article

References (17)

1. R.C. Parish, and J.D. Evans Inflammation in chronic heart failure Ann Pharmacother 42 2008 1002 1016
2. B.W. Van Tassell, S. Toldo, E. Mezzaroma, and A. Abbate Targeting interleukin-1 in heart disease Circulation 128 2013 1910 1923
3. B.W. Van Tassell, R.A. Arena, and S. Toldo et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure PLoS One 7 2012 e33438
4. B.W. Van Tassell, R. Arena, and G. Biondi-Zoccai et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure with preserved ejection fraction (from the D-HART pilot study) Am J Cardiol 113 2 2014 321 327
5. B.A. Borlaug, and W.J. Paulus Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment Eur Heart J 32 2011 670 679
6. J. Gardin, D. Adams, and P. Douglas et al. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report J Am Soc Echocardiogr 15 2002 275 290
7. G.J. Balady, R. Arena, and K. Sietsema et al. Clinician's guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association Circulation 122 2010 191 225
8. L.P. Cahalin, P. Chase, and R. Arena et al. A meta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure Heart Fail Rev 18 2013 79 94
9. R. Arena, R. Humphrey, and M.A. Peberdy Relationship between the Minnesota Living With Heart Failure Questionnaire and key ventilatory expired gas measures during exercise testing in patients with heart failure J Cardiopulm Rehabil 22 2002 273 277
10. L.C. Davies, R. Wensel, and P. Georgiadou et al. Enhanced prognostic value from cardiopulmonary exercise testing in chronic heart failure by non-linear analysis: oxygen uptake efficiency slope Eur Heart J 27 2006 684 690
11. J.T. Parissis, M. Nikolaou, and D. Birmpa et al. Clinical and prognostic value of Duke's Activity Status Index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Am J Cardiol 103 2009 73 75
12. N. Lamblin, F. Mouquet, and B. HEnnache et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure Eur Heart J 26 2005 2245 2250
13. J.J. McMurray, J. Kjekshus, and L. Gullestad et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis Circulation 120 2009 2188 2196
14. P.M. Ridker, T. Thuren, A. Zalewski, and P. Libby Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Am Heart J 162 2011 597 605
15. M. Guazzi, and R. Arena The impact of pharmacotherapy on the cardiopulmonary exercise test response in patients with heart failure: a mini review Curr Vasc Pharmacol 7 2009 557 569
16. M. Guazzi, V. Labate, L.P. Cahalin, and R. Arena Cardiopulmonary exercise testing reflects similar pathophysiology and disease severity in heart failure with reduced and preserved ejection fraction Eur J Prev Cardiol 2013 [ http://www.ncbi.nlm.nih.gov/pubmed/23382540 ]
17. L.B. Daniels, and A.S. Maisel Natriuretic peptides J Am Coll Cardiol 50 2007 2357 2368